Key Insights:
- The American Gastroenterological Association has issued new guidelines for using endoscopic eradication therapy (EET) in patients with Barrett’s esophagus (BE). EET is strongly recommended for patients with high-grade dysplasia and conditionally recommended for those with low-grade dysplasia.
- For patients with visible lesions, focal endoscopic mucosal resection (EMR) plus ablation is preferred over stepwise EMR. The choice between EMR or endoscopic submucosal dissection should be based on lesion characteristics.
- Surveillance endoscopy can be chosen by patients with low-grade dysplasia who prioritize avoiding potential harms over the uncertain benefits of reducing esophageal cancer mortality.
The updated guidelines emphasize personalized treatment approaches for Barrett’s esophagus, particularly advocating for endoscopic eradication therapy in cases of high-grade dysplasia and offering conditional recommendations for other stages, tailored to patient preferences and lesion characteristics.